Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
ID: 331840Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/331840

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-136.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the R33 Exploratory/Developmental Grants Phase II funding opportunity, aimed at early-stage testing of pharmacologic and device-based interventions for mental disorders. This initiative seeks to support studies that validate molecular or circuit-based targets and assess their impact on clinical outcomes for conditions such as schizophrenia, depression, and anxiety, with a focus on innovative interventions that have not yet received FDA approval. The total funding commitment for this opportunity is $27 million, with a proposal deadline of February 15, 2024. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-136-Full-Announcement.html
    PAR-21-136.html
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is soliciting applications for the R33 Exploratory/Developmental Grants Phase II funding opportunity, aimed at early-stage testing of pharmacologic and device-based interventions for mental disorders. This initiative focuses on studies to validate molecular or circuit-based targets and determine their effect on clinical outcomes in conditions such as schizophrenia, depression, and anxiety. The funding supports innovative interventions that are not yet FDA approved and encourages collaboration between academic and industry researchers. Key requirements include demonstrating preliminary data on target engagement and ensuring all involved interventions have passed Phase I safety studies. The proposal deadline is February 15, 2024, and the anticipated number of awards includes a total funding commitment of $27 million for related projects. The document outlines eligibility criteria, application requirements, evaluation metrics, and guidance on data sharing via the National Data Archive, reflecting NIH’s commitment to advancing research on mental health interventions.
    Similar Opportunities
    Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required). This initiative aims to support innovative clinical trials that investigate novel interventions for mental health conditions, including schizophrenia, depression, and anxiety, with a focus on establishing proof of mechanism and target engagement in the R61 phase and confirming findings on a larger scale in the R33 phase. The total funding commitment for this initiative is $27 million for FY 2022, and eligible applicants include a diverse range of entities such as higher education institutions, nonprofits, and various government organizations, both domestic and foreign. Interested parties should note that the application deadline is October 15, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries.
    Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering a funding opportunity for the Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). This initiative aims to support pilot research focused on innovative psychosocial intervention strategies for both adults and children, emphasizing the experimental therapeutic approach to address underlying mechanisms of mental disorders. The funding will facilitate exploratory clinical trials for up to three years, with no specific budget limits, provided they reflect actual project needs, and applications must demonstrate a strong scientific rationale and empirical support. Interested applicants can find more information and application details at the provided NIH link, with a submission deadline of October 15, 2024.
    NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering the Exploratory/Developmental Research Grant (R21), which aims to support high-risk and innovative research projects that align with the mission of advancing mental health research. This grant is specifically designed for the early stages of research that may lead to significant breakthroughs in clinical and biomedical fields related to mental health, with a funding limit of $275,000 over a two-year period. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal governments, emphasizing the importance of innovative approaches in addressing critical barriers in mental health research. Interested parties should note that applications are due by January 7, 2025, and must adhere to NIH guidelines, with further inquiries directed to grantsinfo@nih.gov.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at fostering the development of innovative brain stimulation devices or enhancing existing FDA-approved devices for treating mental health disorders. The initiative seeks applications from multi-disciplinary teams with expertise in neuroscience, engineering, clinical practices, and regulatory matters, focusing on creating devices that offer improved spatial and temporal resolution compared to current technologies. This funding opportunity is critical for advancing treatment methods in mental health care, with no budget limits as long as costs align with project needs, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health treatment. This grant supports projects that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices, focusing on improving spatial and temporal precision and enabling multi-focal approaches for effective treatment delivery. The initiative is crucial for addressing clinical limitations in mental health technologies and encourages collaboration among multidisciplinary teams with expertise in neuroscience, engineering, and regulatory affairs. Interested applicants can apply for up to $275,000 over a two-year project period, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-038.html.
    Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders" (R61/R33 Clinical Trial Required). This initiative aims to support pilot research that develops and tests innovative psychosocial interventions targeting mental disorders in both adults and children, focusing on early-stage exploratory clinical trials to assess how these interventions engage biological, cognitive, or behavioral targets linked to mental health issues. Successful projects will receive funding for up to two years in the R61 phase for preliminary studies, with the potential for an additional three years in the R33 phase contingent upon meeting specified milestones. Interested applicants must adhere to strict guidelines regarding human subject protections and submit their applications through Grants.gov by the deadline of October 15, 2024. For further inquiries, applicants can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV.
    Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) grant. This funding opportunity aims to support clinical trials that assess the efficacy of non-pharmacological interventions for mental disorders in both adults and children, focusing on addressing unmet therapeutic needs and enhancing understanding of the mechanisms of action through rigorous experimental therapeutics approaches. The NIMH plans to commit approximately $27 million to fund various companion funding opportunities, with applications due by October 15, 2024. Interested applicants can find additional information and application procedures at the provided NIH link or contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This funding initiative aims to support invasive neural recording studies that address mental health-related questions, focusing on understanding the neural circuitry and dynamics underlying complex behaviors, emotions, and cognitive functions. The R21 grant mechanism encourages innovative, short-term research proposals with a budget of up to $275,000 over two years, while emphasizing the importance of diverse research teams from various clinical fields. Interested applicants should note that the application deadline is January 7, 2025, and can find further details and guidelines at the NIH grants website or by contacting NIH Grants Information at grantsinfo@nih.gov.